

NS Health COVID-19 Medication Recommendations

Recommendation	Medication	Notes
Routine Care	Dexamethasone	Use for individuals with SpO2 less than or equal to 94% on room air or supplemental oxygen, or mechanical ventilation (including ECMO).
	Inhaled Budesonide	Use on a case-by-case basis in individuals with non-severe symptomatic COVID-19 (do not require: new or additional supplemental oxygen, intravenous fluids, or physiological support) within 14 days of symptom onset.
	Nirmatrelvir/ ritonavir	Use on a case-by-case basis in individuals with non-severe symptomatic COVID-19, confirmed by a positive COVID-19 test, who are at high risk for progression to severe disease. To be ordered by a designated prescriber while in a prioritization* phase.
	Remdesivir**	Non-severe disease: Use on a case-by-case basis in individuals with non-severe symptomatic COVID-19, confirmed by a positive COVID-19 test, who are at high risk for progression to severe disease. To be ordered by a designated prescriber while in a prioritization* phase after consideration for other available therapeutics. Moderate-severe disease: Use in hospitalized patients with symptomatic moderate to severe COVID-19. To be ordered by a designated prescriber while in a prioritization* phase.
	Sotrovimab	Use on a case-by-case basis in individuals with non-severe symptomatic COVID-19, confirmed by a positive COVID-19 test, who are at high risk for progression to severe disease. To be ordered by a designated prescriber while in a prioritization* phase.
Research	Baricitinib	Use in the context of pragmatic research (e.g.: the CO-VIC study) in patients with moderate to severe symptomatic COVID-19.
	Sarilumab	Use on a case-by-case basis in the context of pragmatic research (e.g.: the CO-VIC study) in patients with severe symptomatic COVID-19 requiring critical care for organ support.
	Tocilizumab	Use in the context of pragmatic research (e.g.: the CO-VIC study) in hospitalized patients with severe COVID-19, SpO2 less than or equal to 92% on room air or supplemental oxygen, and systemic inflammation (e.g.: CRP >75 mg/L) in addition to standard of care.
Do NOT Recommend	Bamlanivimab, Casirivimab/imdevimab, Colchicine, Fluvoxamine, Ivermectin	

* Prioritization phase is in place to ensure sustainability and appropriate use during a time of rapidly changing evidence and supply **Recommendation for use varies depending on COVID-19 disease severity

COVID Severity Definitions: **Asymptomatic:** No COVID-19 symptoms. **Non-severe:** *Mild illness*= COVID-19 symptoms WITHOUT evidence of lower respiratory disease (e.g.: shortness of breath, dyspnea, or abnormal chest imaging) AND SpO2 ≥94% OR no change from oxygen saturation at baseline, *Moderate illness* = Evidence of lower respiratory disease (e.g.: shortness of breath, dyspnea, or abnormal chest imaging) AND SpO2 ≥ 94% OR no change from oxygen saturation at baseline. **Severe:** SpO2 <94% on room air or supplemental oxygen. **Critical illness:** Respiratory failure, septic shock, and/or multiple organ dysfunction.